Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.49 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19783967 | 0.90 | CA2 (0.51) | SIRT2SIRT1SIRT3SIRT5MMP1 | |
| SCHEMBL20282050 | 0.90 | CA2 (0.51) | SIRT2SIRT1SIRT3SIRT5MMP1 | |
| SCHEMBL18820236 | 0.88 | MMP1 (0.54) | SIRT2SIRT1SIRT3SIRT5MMP1 | |
| SCHEMBL17750718 | 0.87 | SIRT5 (0.57) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL17039855 | 0.87 | SIRT5 (0.57) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL17750717 | 0.87 | SIRT5 (0.56) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL17039859 | 0.87 | SIRT5 (0.56) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL23286132 | 0.86 | HDAC8 (0.52) | CTSL | |
| SCHEMBL8242077 | 0.85 | CTSL (0.62) | SIRT2CTSLMMP1MMP3MMP9 | |
| SCHEMBL8245679 | 0.85 | CTSL (0.62) | SIRT2CTSLMMP1MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618935-B2 | Antibody-drug conjugate (ADC) and method for forming the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-04-14 | — | — | US | disclosed |
| US-20190106459-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-04-11 | — | — | US | disclosed |
| US-10233212-B2 | Compounds, linker-drugs and ligand-drug conjugates | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-03-19 | — | — | US | disclosed |
| US-20180016300-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016300-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | SLC43A1, HCAR3, SLC7A1 | SIRT2 1659/4885SIRT1 1167/4885SIRT3 740/4885 |
| US-10233212-B2 | Compounds, linker-drugs and ligand-drug conjugates | SLC43A1, HCAR3, SLC7A1 | SIRT2 1659/4885SIRT1 1167/4885SIRT3 740/4885 |
| US-10618935-B2 | Antibody-drug conjugate (ADC) and method for forming the same | DNPEP, DLST, DDOST | SIRT2 3068/4885SIRT1 2423/4885SIRT3 2204/4885 |
| US-20190106459-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | SLC43A1, HCAR3, SLC7A1 | SIRT2 1659/4885SIRT1 1167/4885SIRT3 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.